Resize1
Autonomix Announces 83% Reduction of Pain at 4-6 Week Follow-Up from Lead-In Patients in Ongoing Human Clinical Trial in Pancreatic Cancer Pain Patients
September 09, 2024 07:00 ET | Autonomix Medical, Inc.
Responders experienced a pain reduction from a pre-procedure pain score of 8 to a pain score of 1.33 at 4-6 weeks post-procedure 60% of patients responded with a mean 6.67 or 83% reduction...
Acrivon logo.jpg
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
September 09, 2024 07:00 ET | Acrivon Therapeutics, Inc
-Webcast investor event on September 14, 2024 at 9:00 a.m. ET -ESMO poster presentation to provide updated ACR-368 clinical data in endometrial cancer -Webcast to provide updates on its lead assets...
roivantLogo.png
Roivant Provides Update on Graves’ Disease Development Program
September 09, 2024 07:00 ET | Roivant Sciences
High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12High dose batoclimab achieved 56% ATD-free response rate in patients uncontrolled on ATDs...
LOGO New.jpg
Nova Vision Acquisition Corp. Announces Additional Contribution to Trust Account to Extend Period to Consummate Business Combination to October 10, 2024
September 09, 2024 07:00 ET | Nova Vision Acquisition Corp.
Singapore, Sept. 09, 2024 (GLOBE NEWSWIRE) --  Nova Vision Acquisition Corp. (NASDAQ: NOVV, the “Company”), a special purpose acquisition company, announced today that Nova Pulsar Holdings Limited,...
Akero logo with white space 1.jpg
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
September 09, 2024 07:00 ET | Akero Therapeutics Inc.
Outcomes is the third study in the Phase 3 SYNCHRONY clinical trial program SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a...
TilrayBrands_Logo_FullColor_RBG_Horiz-01.png
Tilray Medical Supports Scientific Study on Fibromyalgia With Positive Outcomes: Effectiveness of Cannabinoids Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms
September 09, 2024 07:00 ET | Tilray Brands, Inc.
LISBON, Portugal, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the...
TilrayBrands_Logo_FullColor_RBG_Horiz-01.png
Tilray Medical unterstützt wissenschaftliche Studie zu Fibromyalgie Mit positiven Ergebnissen: Wirksamkeit der Cannabinoid-Behandlung von Schmerzen und anderen mit Fibromyalgie verbundenen Symptomen
September 09, 2024 07:00 ET | Tilray Brands, Inc.
LISSABON, Portugal, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, ein Geschäftsbereich von Tilray Brands, Inc. („Tilray“) (Nasdaq: TLRY; TSX: TLRY) und ein weltweit führender Anbieter von...
TilrayBrands_Logo_FullColor_RBG_Horiz-01.png
Tilray Medical participe à une étude scientifique sur la fibromyalgie avec des résultats positifs : efficacité du traitement aux cannabinoïdes de la douleur et d’autres symptômes associés à la fibromyalgie
September 09, 2024 07:00 ET | Tilray Brands, Inc.
LISBONNE, Portugal, 09 sept. 2024 (GLOBE NEWSWIRE) -- Tilray Medical, division de Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY) et leader mondial du cannabis thérapeutique, qui...
canoo_logoBLK.png
Canoo Expands Presence in Oklahoma and Texas with Engineering Talent and Headquarters Relocation
September 09, 2024 07:00 ET | Canoo, Inc.
Canoo Expands Presence in Oklahoma and Texas with Engineering Talent and Headquarters Relocation
Moonlake logo.png
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
September 09, 2024 07:00 ET | MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage...